Search results with tag "Thromboembolic"
Page 1 of 4 BEVACIZUMAB Bevacizumab in combination with ...
www.londoncanceralliance.nhs.ukA history of arterial thromboembolic events or age over 65 years was associated with an increased risk of developing arterial thromboembolic events during therapy.
Preventing Venous Thromboembolic Disease in Patients ...
www.aaos.orgto this clinical practice guideline filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to beginning work on the recommendations contained within this clinical practice guideline.
IMHA disease in canines – diagnosis and treatment
www.vettimes.co.ukA mild thrombocytopenia may indicate secondary thromboembolic disease. A severe thrombocytopenia is consistent with Evans syndrome, where the platelets are also targeted by the immune system. Serum biochemistry is usually normal or shows changes secondary to dehydration and/or tissue
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euVenous thromboembolic events were reported in 5.3% of patients treated with abemaciclib plus fulvestrant or aromatase inhibitors, compared to 0.8% of patients treated with placebo plus fulvestrant or aromatase inhibitors. Patients should be monitored for signs and symptoms of deep vein thrombosis
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.pi.amgen.com• To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.3)]. • Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.cslbehring.com5.1 Thromboembolic Events (VWD Patients) 5.2 Monitoring for Intravascular Hemolysis 5.3 Monitoring VWF:RCo and FVIII Levels 5.4 Transmission of Infectious Agents 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery
Lynparza Prescribing Information
den8dhaj6zs0e.cloudfront.net5.4 Venous Thromboembolic Events 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Use with Anticancer Agents 7.2 Effect of Other Drugs on Lynparza 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.5 Geriatric Use 8.6 Renal Impairment
Lists of medicinal products for rare diseases in Europe*
www.orpha.netChronic thromboembolic pulmonary hypertension (CTEPH), persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. As monotherapy or in combination with endothelin receptor antagonists, for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eudisease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat-and-extend regimen with gradually increased treatment ... Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have
Peri-Procedure Management of Anticoagulants Page 1 of 29
www.mdanderson.org4 See Appendix I for Thromboembolic Risks 5 If patient is on parenteral anticoagulant, see Appendix F; if on warfarin, see Appendix G; if on DOACs, see Appendix H 6 Refer to Transitioning Between Anticoagulants (for internal use only) to assist with transitioning DOAC to a parenteral anticoagulant Page 2 of 29
Warfarin Reversal Guideline 2012 - SurgicalCriticalCare.net
www.surgicalcriticalcare.net3 devices. The mortality rate in these patients was 30% (50/168). Thirty-six of the 50 deaths (72%) were attributed to the thromboembolic event (10)
RXFILES TRIAL SUMMARY O P B LK N 2012 F ARISTOTLE: vs ...
www.rxfiles.caRXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY:M JIN, REVISED LKOSAR –UPDATED NOV 2012 WWW.RXFILES.CA Page 1 of 3 ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation 1 Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation
HIGHLIGHTS OF PRESCRIBING INFORMATION Treatment of …
docs.boehringer-ingelheim.com1.5 Treatment of Venous Thromboembolic Events in Pediatric Patients PRADAXA Capsules is indicated for the treatment of venous thromboe mbolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days (see Dosage and Administration [2.3]).
Thromboembolic Disease in Pregnancy and the Puerperium ...
www.rcog.org.ukThromboembolic Disease in Pregnancy and the Puerperium: Acute Management This is the third edition of this guideline. The first edition was published in April 2001 under the same title (numbered Green-top Guideline No. 28) and the second edition was published in February 2007 and reviewed in 2010.
Similar queries
BEVACIZUMAB Bevacizumab in combination with, ThromboemboLic Events, Preventing Venous Thromboembolic Disease in, Clinical practice guideline, Disease, Thromboembolic disease, SUMMARY OF PRODUCT CHARACTERISTICS, Thromboembolic, Prescribing Information, Pregnancy, Lists of medicinal products for rare diseases, Management, Warfarin Reversal Guideline, RXFILES TRIAL SUMMARY O P, ARISTOTLE, Thromboe mbolic, Thromboembolic Disease in Pregnancy and, Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management